Literature DB >> 21641053

Evaluation of neointimal coverage and apposition with various drug-eluting stents over 12 months after implantation by optical coherence tomography.

Shan Li1, Yutang Wang, Luyue Gai, Tingshu Yang, Hongbin Liu, Zhifeng Wang, Qicai Bai, Xiuli Xu, Yundai Chen.   

Abstract

BACKGROUND: Optical coherence tomography (OCT) is an imaging technology with high resolution which provides new opportunities for evaluating the vascular healing reaction after stent implantation. We used OCT to compare neointimal coverage and stent strut apposition with different types of drug-eluting stent (DES) at more than 12 months follow-up.
METHODS: Fifty five patients who accepted 72 DESs (19 sirolimus-eluting stents [SES, Cypher Select], 27 paclitaxel-eluting stents [PES, Taxus Liberte], 26 zotarolimus-eluting stents [ZES, Endeavor]) were enrolled in our study. OCT was performed at 12-18 months after stent implantation. The neointimal hyperplasia (NIH) thickness and stent strut apposition at 1-mm interval and the presence of thrombus in each stent were observed.
RESULTS: The average NIH thickness (0.1806 ± 0.1726 mm in SES vs. 0.2558 ± 0.2187 mm in PES vs. 0.2983 ± 0.2567 mm in ZES, p<0.001) and percentage of NIH area (17.21 ± 14.05% in SES vs. 23.09 ± 14.53% in PES vs. 28.73 ± 20.47% in ZES, p=0.002) were significantly greater in ZES than in other DESs. The prevalence of uncovered struts (8.96% in SES vs. 6.19% in PES vs. 2.98% in ZES, p<0.01) and malapposed struts (6.36% in SES vs. 2.32% in PES vs. 1.69% in ZES, p<0.01) was significantly lower in ZES than in other DESs. Thrombus was less frequently observed in ZES than in other DESs (SES 1.70% vs. PES 0.83% vs. ZES 0.17%, p<0.01).
CONCLUSIONS: Compared with SES and PES, ZES showed lower prevalence of uncovered struts and malapposed struts at more than 12 months follow-up.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21641053     DOI: 10.1016/j.ijcard.2011.05.076

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.

Authors:  Petr Toušek; Viktor Kočka; Martin Malý; Libor Lisa; Tomáš Buděšínský; Petr Widimský
Journal:  Heart Vessels       Date:  2015-04-21       Impact factor: 2.037

Review 2.  Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights.

Authors:  Daniel S Ong; Ik-Kyung Jang
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

3.  Optimization of Drug Delivery by Drug-Eluting Stents.

Authors:  Franz Bozsak; David Gonzalez-Rodriguez; Zachary Sternberger; Paul Belitz; Thomas Bewley; Jean-Marc Chomaz; Abdul I Barakat
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

4.  The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxcel eluting stent and zotarolims eluting stent.

Authors:  Suguru Murase; Yoriyasu Suzuki; Toshikazu Yamaguchi; Osamu Matsuda; Akira Murata; Tatsuya Ito
Journal:  Catheter Cardiovasc Interv       Date:  2014-02-15       Impact factor: 2.692

5.  Characteristics of Earlier Versus Delayed Presentation of Very Late Drug-Eluting Stent Thrombosis: An Optical Coherence Tomographic Study.

Authors:  Seung-Yul Lee; Jung-Min Ahn; Gary S Mintz; Seung-Ho Hur; So-Yeon Choi; Sang-Wook Kim; Jin Man Cho; Soon Jun Hong; Jin Won Kim; Young Joon Hong; Sang-Gon Lee; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Seung-Jung Park; Myeong-Ki Hong
Journal:  J Am Heart Assoc       Date:  2017-04-14       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.